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Glyoxalase 1 (GLO1) is a ubiquitous cellular enzyme that participates in the detoxification
of methylglyoxal (MG), a cytotoxic byproduct of glycolysis that induces protein
modification (advanced glycation end-products, AGEs), oxidative stress, and apoptosis.
The concentration of MG is elevated under high-glucose conditions, such as diabetes. As
such, GLO1 and MG have been implicated in the pathogenesis of diabetic complications.
Recently, findings have linked GLO1 to numerous behavioral phenotypes, including
psychiatric diseases (anxiety, depression, schizophrenia, and autism) and pain. This review
highlights GLO1’s association with behavioral phenotypes, describes recent discoveries
that have elucidated the underlying mechanisms, and identifies opportunities for future
research.
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BACKGROUND
Glyoxalase 1 (GLO1) is an enzyme in the glyoxalase sys-
tem, a metabolic pathway that detoxifies α-oxoaldehydes, par-
ticularly methylglyoxal (MG) (Thornalley, 1990, 1993, 2003a;
Mannervik, 2008). MG is primarily formed by the degrada-
tion of the glycolytic intermediates, dihydroxyacetone phos-
phate, and glyceraldehyde-3-phosphate (Thornalley, 1993). MG
levels rise under high-glucose conditions, such as diabetes
(Brownlee, 2001). At supra-physiological levels, MG induces
protein and nucleotide modification (advanced glycation end-
products, AGEs), reactive oxygen species (ROS), and apoptosis
(Brownlee, 2001; Thornalley, 2003b). AGEs cause dysfunction
of affected proteins (Brownlee, 2001) and ligate the receptor for
advanced glycation end-products (RAGE), triggering the produc-
tion of ROS (Schleicher and Friess, 2007) and apoptosis (Loh
et al., 2006). To combat MG’s cytotoxic effects, GLO1 enzy-
matically converts MG into the less reactive substance, d-lactate
(Thornalley, 2003b). In vitro, overexpression of Glo1 prevents
MG accumulation (Shinohara et al., 1998); conversely, GLO1
inhibition increases MG accumulation and decreased cellular via-
bility (Kuhla et al., 2006). Given their roles in AGE formation
and cytotoxicity, GLO1 and MG have been implicated in dis-
eases where these effects are relevant to pathogenesis, such as
diabetic complications (i.e., micro- and macro-vascular disease),
cancer, and aging (Brownlee, 2001; Thornalley, 2003a; Ahmed
and Thornalley, 2007; Morcos et al., 2008; Fleming et al., 2010;
Thornalley and Rabbani, 2011).
Surprisingly, an increasing number of studies have identified
associations between GLO1 and behavioral phenotypes. In mice,
several lines of evidence suggest that Glo1 expression is associated
with anxiety-like behavior (Hovatta et al., 2005; Reiner-Benaim
et al., 2007; Loos et al., 2009; Benton et al., 2011; Distler et al.,
2012), depression (Benton et al., 2011), and neuropathic pain
(Jack et al., 2011, 2012; Bierhaus et al., 2012). New observa-
tions in rats using oxidative stress models (Salim et al., 2010a,b)
and the sleep-deprivation model of psychological stress (Vollert
et al., 2011), both suggest role of GLO1 in the anxious pheno-
type of rats (Salim et al., 2011). Additional associations have been
identified with habituation, locomotor activity, motor coordina-
tion, exploratory behavior, and learning and memory (Williams
et al., 2009). In humans, genetic studies have implicated poly-
morphisms in GLO1 in panic disorder (Politi et al., 2006),
depression (Fujimoto et al., 2008), autism (Junaid et al., 2004;
Barua et al., 2011), schizophrenia (Arai et al., 2010; Toyosima
et al., 2011), and restless legs syndrome (RLS) (Stefansson et al.,
2007; Winkelmann et al., 2007, 2011; Kemlink et al., 2009).
While the studies of RLS identify a haplotype block that includes
GLO1, more attention has been paid to the neighboring gene
BTBD9. The other human genetic studies utilized a candidate
gene approach and had small sample sizes; in most cases, those
results have not been replicated. Aside from genome-wide asso-
ciation studies (GWAS) of RLS, GLO1 has not been identified in
GWAS for other psychiatric or neurological traits.
Recently, two major studies have shed light on the mecha-
nisms underlying GLO1’s behavioral effects. One identified MG
as an agonist at GABAA receptors (Distler et al., 2012), while the
other identified MG modification of voltage-gated sodium chan-
nels (Bierhaus et al., 2012). This article will focus on GLO1’s
behavioral correlates and the potential underlying mechanisms.
The basic biochemistry of GLO1 has been reviewed elsewhere
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(Thornalley, 1990, 1993, 2003b), as have its roles in cancer
(Thornalley, 2003a; Thornalley and Rabbani, 2011) and diabetic
complications (Brownlee, 2001; Ahmed and Thornalley, 2007;
Schleicher and Friess, 2007; Jack and Wright, 2012; Rabbani and
Thornalley, 2012).
GLO1’S BEHAVIORAL CORRELATES
ANXIETY
Mouse genetic studies
Among the behavioral phenotypes associated with GLO1,
anxiety-like behavior is the most commonly reported and widely
studied. In mice, numerous genetic studies have identified asso-
ciations between Glo1 expression and anxiety-like behavior
(Hovatta et al., 2005; Kromer et al., 2005; Williams et al., 2009).
Hovatta et al. analyzed gene expression profiles in a panel of six
inbredmouse strains, which were scored for anxiety-like behavior
in the open field and light-dark box tests (Hovatta et al., 2005).
They found a positive correlation between Glo1 expression and
anxiety-like behavior. Several subsequent studies also identified
positive correlations between Glo1 expression and anxiety-like
behavior among inbred mouse strains (Reiner-Benaim et al.,
2007; Loos et al., 2009; Benton et al., 2011).
Importantly, Hovatta et al. established a causal role for Glo1
in anxiety-like behavior by using viral vectors to overexpress or
knock down Glo1 in the anterior cingulate cortex (Hovatta et al.,
2005). Local Glo1 overexpression increased anxiety-like behav-
ior, while local Glo1 knockdown decreased anxiety-like behavior
(Hovatta et al., 2005). This experimental manipulation supported
a causal role for Glo1 in anxiety-like behavior. However, this study
was limited by the use of viral vectors: expression was manipu-
lated only in one brain region during adulthood. As such, it might
not have accurately modeled Glo1’s normal physiological role in
anxiety-like behavior. Furthermore, viral vectors often produce
variable expression levels between animals (Kirik and Bjorklund,
2003).
Kromer et al. also identified a correlation between GLO1 and
anxiety-like behavior in mice (Kromer et al., 2005). They selec-
tively bred mice for high anxiety-like behavior (HAB) or low
anxiety-like behavior (LAB) and subsequently inbred the mice to
generate two lines. The LAB line had higher GLO1 protein lev-
els than the HAB line (Kromer et al., 2005). Therefore, Kromer
et al. proposed that increased GLO1 was a biomarker for low
anxiety-like behavior, a result directionally opposite from stud-
ies that used panels of inbred mouse strains (Hovatta et al., 2005;
Reiner-Benaim et al., 2007; Loos et al., 2009; Benton et al., 2011)
and those that used viral vectors to manipulate Glo1 expression
(Hovatta et al., 2005). In fact, the discrepancy among these stud-
ies was used as grounds to dispute a role for Glo1 in anxiety-like
behavior (Thornalley, 2006).
A subsequent study identified a common copy number vari-
ant (CNV) among inbred mice that caused a duplication of
four genes, including Glo1 (Williams et al., 2009). Of the 72
inbred strains examined, 23 carried the duplication. The dupli-
cation was positively correlated with increased Glo1 expression
(it was an expression QTL; eQTL) and increased anxiety-like
behavior (Williams et al., 2009). Increased Glo1 copy num-
ber was also associated with other behavioral phenotypes that
were available from public databases, including locomotor habit-
uation in a novel environment (negative correlation), total
locomotor activity (positive correlation), motor coordination
(positive correlation), rearing (positive correlation), anxiety-
like behavior in the elevated plus maze and light-dark box
tests (positive correlation), stretch-attends in tests of anxiety-
like behavior (negative correlation), and measures of learning
and memory (Williams et al., 2009). These findings suggested
a role for Glo1 copy number in a broad range of behavioral
phenotypes.
The discovery of this CNV helped to explain the previously
reported differences in Glo1 expression among inbred strains
(Hovatta et al., 2005). In addition, it explained the differential
GLO1 protein expression reported in the HAB and LAB lines:
LABmice were subsequently shown to have the duplication, while
HAB mice do not (Hambsch et al., 2010). Although it is some-
what surprising that selection did not have the opposite result,
other factors, including differences in initial allelic frequencies,
linked alleles, and drift before or during inbreeding could have
contributed to the fixation of the duplication in LAB but not
HAB mice. The effect of the Glo1 duplication on anxiety-like
behavior was likely offset by numerous other alleles that collec-
tively contributed to anxiety-like behavior in the selected lines.
HAB and LAB lines are known to harbor many genetic differ-
ences due to selection and inbreeding (Bunck et al., 2009; Ditzen
et al., 2010; Czibere et al., 2011; Filiou et al., 2011; Tasan et al.,
2011; Zhang et al., 2011). Indeed, selection studies are prone to
such confounding forces, especially when the selected lines are not
replicated.
The discovery of the Glo1 CNV also raised the possibility that
Glo1 expression could simply be a marker for the presence of
the CNV rather than directly regulating anxiety-like behavior.
Specifically, the CNV contained four genes, any of which could
have affected behavioral phenotypes. Further, the CNV could
have been linked to unidentified causal alleles or could have dis-
rupted neighboring genes. As such, the discovery of the CNV
complicated observed associations between Glo1 expression and
behavior.
Therefore, in order to test the hypothesis that increased Glo1
expression was sufficient to replicated the behavioral differences
associated with the CNV, targeted genetic manipulation of Glo1
copy number performed in which mice with a transgenic bacte-
rial artificial chromosome (BAC) containing Glo1 were created to
model the CNV (Distler et al., 2012). To isolate Glo1’s effect, the
BAC was engineered so that only Glo1 was expressed. BAC trans-
genic mice overexpressed Glo1 and displayed increased anxiety-
like behavior. This effect was observed in multiple founder lines
and on two genetic backgrounds: C57BL/6J (B6) and FVB/NJ
(FVB). The effect of Glo1 overexpression on anxiety-like behav-
ior was strongest in the lines with the highest copy numbers.
Unlike the viral vector studies (Hovatta et al., 2005), this study
demonstrated the physiological relevance of Glo1 in behavior,
because Glo1 was expressed under its endogenous promoter ele-
ments, in its natural expression pattern, and throughout the
animal’s life. Therefore, this study demonstrated that increased
Glo1 copy number increased Glo1 expression and anxiety-like
behavior.
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Human genetic studies of GLO1 and anxiety
In contrast to mouse studies, human genetic studies have not
identified robust associations between GLO1 and anxiety disor-
ders. In humans, there are two common GLO1 alleles (Kompf
et al., 1975) that result from a single nucleotide polymor-
phism (SNP) at position 419 (Kim et al., 1995). Adenine (419A)
encodes a glutamate at amino acid 111 (111E), and cytosine
(419C) encodes an alanine (111A). Politi et al. (2006) identi-
fied a weak, but significant increase in the risk of panic disorder
without agoraphobia among people carrying the 419A allele.
Limitations, such as the small sample size and potential popu-
lation stratification, made this result preliminary. A subsequent
study found no correlation between GLO1 expression and sus-
ceptibility to panic attacks (Eser et al., 2011), but suffered from
the same limitations, so cannot be said to disprove the origi-
nal observation. Similarly, no published GWAS studies of panic
disorder have identified GLO1 (Erhardt et al., 2011). Despite dis-
appointing findings from human genetic studies, there remains
a need for large, carefully controlled genetic studies in order
to address whether differences in GLO1 affect anxiety among
humans.
DEPRESSION
There is strong evidence for shared genetic vulnerability to anx-
iety and depression (Cerda et al., 2010). Among a panel of
inbred mice, Benton et al. found a positive correlation between
GLO1 protein levels and baseline depression-like behavior using
the tail-suspension test (Benton et al., 2011), suggesting that
Glo1 could contribute to the common genetic etiology of anx-
iety and depression. However, a small human study of GLO1
and depression reported apparently conflicting data. Fujimoto
et al. reported a negative correlation between GLO1 expres-
sion and depression in humans (Fujimoto et al., 2008). GLO1
mRNA expression was reduced in peripheral white blood cells
(WBC) of patients with major depressive and bipolar disorders
(Fujimoto et al., 2008). GLO1 mRNA expression did not signifi-
cantly differ between patients in remission and healthy controls,
suggesting that reduced GLO1 expression was a state-dependent
marker for depression (Fujimoto et al., 2008). However, this
study did not establish whether reduced GLO1 expression affected
GLO1 protein levels or enzymatic activity, which would reflect
the functional significance of differences in mRNA expression.
Further, WBC mRNA may not adequately reflect mRNA expres-
sion in the brain (Mehta et al., 2010). Corroborating findings
from post-mortem brain samples would significantly strengthen
the association between GLO1 expression and depression (Mehta
et al., 2010). Therefore, although data from mice implicate Glo1
in increasing depression-like behavior, further experiments are
required to resolve the discrepancy with human data.
AUTISM
Human studies have proposed an association between a cod-
ing SNP in GLO1 (419A/C; rs2736654) and autism. Junaid et al.
reported that the 419A allele was 1.5 times more common among
autistic patients than controls (Junaid et al., 2004). However, this
study was limited by its small sample size and potential confound-
ing variables (e.g., population stratification). Indeed, subsequent
studies have not replicated this finding: there was no associa-
tion between SNPs in GLO1 and autism among Han Chinese
patients (Wu et al., 2008), nor was there significant linkage or
association between SNPs in GLO1 and autism among Finnish
patients (Rehnstrom et al., 2008). Furthermore, a family-based
and case-control study found that the 419A allele was more com-
mon among unaffected siblings of autistic patients, indicating
that it might be protective (Sacco et al., 2007). Finally, several
human genome-wide association studies (GWAS) have failed to
identify associations between GLO1 polymorphisms and autism.
At the very least, this suggests that the study of Junaid et al. over-
estimated the effect size of this allele, which must have been small
enough to escape detection by larger GWAS.
Nevertheless, Junaid et al. suggested that the 419A GLO1 allele
was associated with a functional change in GLO1 enzymatic activ-
ity. They reported that post-mortem brain tissue from autistic
patients had reduced GLO1 enzymatic activity and increased AGE
content compared to that from control patients (Junaid et al.,
2004). In a later study, Baura et al. reported a correlation between
the 111E GLO1 isoform and reduced enzymatic activity (Barua
et al., 2011). However, Barua et al. did not directly examine enzy-
matic activity of the isoforms. Rather, they utilized cell extracts
derived from autistic and control patients. As such, differences
in enzymatic activity and MG concentration could have resulted
from differences in GLO1 expression or other genetic differences.
Therefore, further studies will help determine the functional
significance of the 419A/C SNP and its contribution to autism.
Experimental studies in mice may help determine whether
GLO1 is related to autism-like behaviors. Various behavioral
assays have been proposed for measuring autism-like phenotypes
in mice, including social interaction tests, ultrasonic vocalization
measurements, assessment of repetitive and stereotyped behavior,
and reversal learning tests (Silverman et al., 2010). In future stud-
ies, these assays may be used to study mutant mice with increased
or decreased Glo1 expression.
SCHIZOPHRENIA
Recently, two studies have suggested a role for GLO1 in
schizophrenia (Arai et al., 2010; Toyosima et al., 2011). In a
single schizophrenic patient, a frameshift mutation in GLO1
was correlated with reduced GLO1 enzymatic activity (Toyosima
et al., 2011). In a separate study, schizophrenic patients were
found to have increased AGE accumulation compared to control
subjects (Arai et al., 2010), suggesting reduced GLO1 func-
tion. Nevertheless, small sample sizes and confounding vari-
ables made these associations preliminary. Therefore, additional
human genetic studies and studies of GLO1 in mice will help
establish an association with schizophrenia. Several behavioral
assays of schizophrenia-like behavior have been proposed (Young
et al., 2010), which could be used for studying mice with aberrant
Glo1 expression.
RESTLESS LEGS SYNDROME
Multiple genome-wide association studies have implicated a
haplotype block that includes GLO1 in restless legs syndrome
(Stefansson et al., 2007; Winkelmann et al., 2007, 2011; Kemlink
et al., 2009). These studies have focused on BTBD9, another gene
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that, like GLO1, is in this largely non-recombinant haplotype,
but this association could also reflect regulatory changes that
impact GLO1.
PAIN
Neuropathic pain is a feature of neuropathy, a common sequela
of diabetes (Vinik et al., 2000; Edwards et al., 2008). There is
an extensive literature on the relationship between Glo1 and
neuropathy which has been recently reviewed (Jack and Wright,
2012). Recent studies have identified associations between the
Glo1 CNV in mice and behavioral measures of neuropathic pain
(Jack et al., 2011, 2012). After diabetes induction, A/J mice,
which carry a triplication of the Glo1 allele, were less sensi-
tive to mechanical pain than B6 mice, which have only a single
copy of Glo1 (Jack et al., 2011). Similarly, Glo1 copy number
was associated with mechanical pain sensitivity after induction
of diabetes in two closely related inbred strains, BALB/cJ and
BALB/cByJ. BALB/cByJ mice carry the Glo1 duplication, while
BALB/cJ mice do not (Williams et al., 2009). Similar to the pre-
vious report, increased levels of Glo1 protected against diabetic
hyperalgesia in BALB/cByJ mice compared to BALB/cJ mice (Jack
et al., 2012). These results suggested that Glo1 mediates behav-
ioral responses to pain associated with diabetic neuropathy. A
recent study has confirmed that GLO1 protects against neuro-
pathic pain associated with diabetes. Overexpression of human
GLO1 reduced thermal hyperalgesia in diabetic mice (Bierhaus
et al., 2012). Conversely, pharmacological inhibition of GLO1
and Glo1 knockdown exacerbated both mechanical and thermal
hyperalgesia in diabetic mice (Bierhaus et al., 2012). Together,
these findings suggest a role for GLO1 in mediating behavioral
measures of pain, particularly that related to diabetic neuropa-
thy. To date, no study has investigated the role of GLO1 in other
types of pain, such as nociceptive and central pain, which is an
important area of future investigation.
GLO1’S MECHANISM OF ACTION IN BEHAVIOR
MG REGULATES BEHAVIOR
There is robust evidence that GLO1 activity regulates MG con-
centration (Thornalley, 1990, 1993, 2003b). Recent studies have
suggested this activity is critical to GLO1’s effects on behav-
ior. In vitro, Glo1 overexpression prevented MG accumulation
under conditions of high glucose (Shinohara et al., 1998), and
in C. elegans, Glo1 overexpression reduced basal MG concentra-
tion (Morcos et al., 2008). Similarly, Glo1 overexpression reduced
baseline MG concentration in the brains of mice (Distler et al.,
2012) and plasma MG concentration in diabetic mice (Bierhaus
et al., 2012).
Given the strong association between GLO1 and MG con-
centration, it was hypothesized that GLO1 affects behavior by
controlling levels of MG. This hypothesis suggested that direct
administration of MG would alter behavior. Recent reports have
demonstrated MG’s behavioral effects, including those related to
anxiety-like behavior (Hambsch et al., 2010; Distler et al., 2012),
depression (Zhang et al., 2011), motor coordination (Distler
et al., 2012), and pain (Bierhaus et al., 2012). Hambsch et al.
administered MG to mice by intra-cereberoventricular injection
daily for 6 days; MG-treated mice displayed reduced anxiety-like
behavior in the elevated plus maze compared to vehicle-treated
mice (Hambsch et al., 2010). Chronic MG treatment also
reduced immobility in the tail suspension test, reflecting an anti-
depressant effect of MG (Hambsch et al., 2010). Distler et al.
identified a similar anxiolytic effect of MG within minutes of
a single intra-peritoneal injection (Distler et al., 2012), suggest-
ing that MG acutely affects behavior. At high doses, acute MG
administration was also shown to have sedative effects, including
locomotor depression, ataxia, hypothermia, and lethargy (Distler
et al., 2012). Acute MG administration also caused hyperalgesia
equivalent to that caused by diabetes in mice (Bierhaus et al.,
2012). Together, these studies indicated that MG concentration
regulates multiple behavioral phenotypes and that MG’s effects
are opposite to those of Glo1 overexpression.
BEHAVIORAL EFFECTS OF PUREMG
The behavioral experiments described above utilized crude
MG preparations, which may contain contaminants, such as
formaldehyde and methanol (Pourmotabbed and Creighton,
1986; McLellan and Thornalley, 1992). We recently tested the
behavioral effects of pure MG and found that it elicited similar
pharmacological effects as crudeMG. At a low dose, pure MGwas
anxiolytic in the open field test, and at a high dose, it caused loco-
motor depression, ataxia, and hypothermia (Distler et al., 2012).
Notably, the doses of pure MG required for sedation, locomotor
depression, ataxia, and hypothermia were similar to the doses of
crude MG, while pure MG elicited an anxiolytic effect at a lower
dose than crude MG. It remains to be determined whether pure
MG affects other reported behavioral effects, such as depression
and hyperalgesia.
MG’S MECHANISMOF ACTION IN BEHAVIOR: AGE FORMATION
MG is best characterized as a cytotoxic agent that forms AGEs.
This molecular action has been attributed to the pathogenesis of
several diseases characterized by increased MG concentrations,
including diabetic complications. For instance, increasedMG lev-
els and subsequent AGE formation have been well-established
pathogenic mechanisms in diabetes-associated microvascular
disease (e.g., diabetic retinopathy) and macrovascular disease
(e.g., atherosclerosis) (Brownlee, 2001).
Recently, AGEs have been attributed to the development of
diabetic neuropathy and neuropathic pain (Jack and Wright,
2012). Induction of diabetes in rats increased AGEs in the extra-
cellular matrix of sensory nerves (Duran-Jimenez et al., 2009).
In particular, laminin and fibronectin were found to be mod-
ified by MG (Duran-Jimenez et al., 2009). Among the numer-
ous proteins likely modified by MG in diabetes (Rabbani and
Thornalley, 2012), a voltage-gated sodium channel, Nav1.8, was
recently reported to be modified by MG and it was suggested that
this modification contribute to neuropathic pain (Bierhaus et al.,
2012). Nav1.8 was MG-modified in peripheral sensory neurons
of mice subjected to diabetes, MG administration, or Glo1 knock
down. Knock down of Nav1.8 reduced MG-induced thermal
hyperalgesia. Finally, MG-modification of Nav1.8 dysregulated
electrical signaling in sensory neurons. Specifically, prolonged
incubation withMG (3–14 h)modified Nav1.8 and altered resting
membrane potential, current threshold, and voltage threshold.
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These findings suggested that AGEs promote protein dysfunction
under conditions of high MG concentrations, thus contributing
to neuropathic pain.
Because MG’s role in AGE formation is well character-
ized, it was thought that this mechanism was relevant to
other behavioral phenotypes, including anxiety-like behavior and
depression (Hambsch, 2011). Hambsch et al. proposed that MG-
dependent AGE formation contributed to MG’s anxiolytic action
(Thornalley, 2006; Hambsch et al., 2010). They found increased
AGEs in the brains of mice treated chronically with MG by
intracerebroventricular administration. Hambsch et al. utilized
a high dose of MG, corresponding to an average concentra-
tion of 1.6mM throughout the brain (assuming a brain volume
of 0.45mL). This study did not establish a causal relationship
between AGE formation and anxiety-like behavior. Therefore, a
role for AGE formation in anxiety-like behavior remains uncer-
tain. Further, the discovery that MG activates GABAA receptors
(discussed below) provides a compelling alternative mechanism
for MG’s anxiolytic effect.
MG’S MECHANISM OF ACTION IN BEHAVIOR: GABAA RECEPTOR
ACTIVATION
A novel role for MG-independent of AGE formation was recently
identified. MG was found to activate GABAA receptors at phys-
iological concentrations (Distler et al., 2012). In vivo, MG’s
pharmacodynamic profile was similar to that of known GABAA
receptor agonists, which are anxiolytic at low doses and have seda-
tive effects at higher doses (Rudolph and Mohler, 2004; Carter
et al., 2009; Kumar et al., 2009). In vitro, MG selectively acti-
vated GABAA receptors and was characterized as a competitive
partial agonist (Distler et al., 2012). There is a wealth of evi-
dence that GABAA receptors play key roles in anxiety (Kent et al.,
2002; Kalueff and Nutt, 2007). As such, MG’s activity at GABAA
receptors can account its anxiolytic effect.
This mechanism is distinct from MG’s previously reported
cellular effects, specifically AGE formation and cytotoxicity. A
low dose of MG was anxiolytic within minutes of peripheral
administration (Distler et al., 2012). This time course differs
from that of AGE formation, which requires hours to days (Lo
et al., 1994). Therefore, AGE formation is unlikely to mediate
MG’s effect on anxiety-like behavior. MG’s anxiolytic effect was
also independent of cytotoxicity. In vitro, MG concentrations of
100–1000μM have been reported to induce neuronal cell death
(Di Loreto et al., 2004, 2008; Li et al., 2010). In contrast, an anx-
iolytic dose of MG only increased the concentration of MG in
the brain to approximately 6μM (Distler et al., 2012). In addi-
tion, MG requires hours to days to induce apoptosis (Di Loreto
et al., 2008), which is inconsistent with the acute time course
(∼10min) of MG’s behavioral effects. Finally, there was no evi-
dence of apoptosis in mice treated with an anxiolytic dose of MG
(Distler et al., 2012). Therefore, MG’s effect at GABAA receptors
occurs at lower concentrations and is temporally dissociable for
its better-known effects, such as AGE formation and cytotoxic-
ity. MG’s GABAergic action may explain previous observations
of MG’s electrophysiological effects. For example, Hambsch et al.
found that incubation with 10μM MG reduced the magnitude
of long-term potentiation (LTP) in hippocampal brain slices
(Hambsch et al., 2010). This is characteristic of GABAA recep-
tor activation, which decreases excitatory post-synaptic potentials
and suppresses LTP in CA1 slices (Seabrook et al., 1997).
IMPLICATIONS OF MG’S ACTIVITY AT GABAA RECEPTORS
MG’s role in activating GABAA receptors has important physio-
logical implications. MG production increases during high gly-
colytic activity. MG can then be metabolized by GLO1, can form
AGEs or can activate GABAA receptors (Figure 1). Importantly,
the effects at GABAA receptors occur at physiological concen-
trations of MG. Similarly, changes in MG concentration that are
associated with diabetes can lead to changes in AGE formation at
a variety of targets, including Nav1.8, which appears to modulate
pain sensitivity.
One physiological function of MG’s activity at GABAA recep-
tors may be to maintain inhibitory tone under conditions of low
GABA concentrations. In the synaptic cleft, the concentration of
GABA is in the millimolar range during synaptic release (Farrant
and Nusser, 2005); in the extracellular space, GABA concentra-
tions are in the submicromolar range (Vithlani et al., 2010). The
concentration of MG in the brain is approximately 5μM (Distler
et al., 2012), and these levels are likely similar in both the synapse
and extracellular space. Therefore, MG is less abundant than
GABA at the synapse; however, in the extracellular space MG is
more abundant than GABA and likely acts as a partial agonist
(Distler et al., 2012). Thus, while it has yet to be well explored MG
may have a complex role in the regulation of GABAergic signaling.
While there are no data to directly support the possibility,
another physiological role for MG may be as a negative
regulator of excitatory signaling. Excitatory synaptic trans-
mission is associated with increased glycolysis (Barros and
Deitmer, 2010). In fact, 60–75% of neuronal glucose utiliza-
tion is estimated to be in glutamatergic neurons (Shulman
et al., 2004). Since neuronal excitation is coupled with gly-
colysis, MG concentrations may increase in excitatory neu-
rons. MG would then activate local GABAA receptors and thus
serve as a negative feedback signal. In addition, it would also
provide inhibitory tone to neighboring cells. Such an action
could be neuroprotective, since excessive N-methyl-D-aspartate
(NMDA) receptor activation by glutamate triggers excitotox-
icity and apoptosis (Naegele, 2007; Henshall and Murphy,
2008).
At the organismal level, MG concentration increases under
conditions of high glucose load. Accordingly, it is possible
that MG concentration may link metabolic state to neuronal
inhibitory tone and behavior, including anxiety. Specifically, high
levels of glucose may be coupled to reduced anxiety through
increased levels of MG. In humans, consumption of foods high in
fat and sugar is associated with emotional reward (Jacquier et al.,
2012). In rats, fructose consumption increased levels of MG in
rats (Wang et al., 2008), which could provide a direct link between
the intake of high-sugar foods and emotional satiety. One notable
exception to the association between increased metabolic load
and reduced anxiety may be in diabetic patients, where elevated
MG level have consistently been observed (Shinohara et al., 1998;
Brownlee, 2001; Masterjohn et al., 2011). There is an increased
prevalence of anxiety among diabetic patients (Anderson et al.,
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FIGURE 1 | A model of the glyoxalase system’s role in GABAergic
signaling. During glycolysis, triose phosphate intermediates can be
converted to MG by non-enzymatic fragmentation. Excess MG is
catabolized by the glyoxalase system (GLO1 and GLO2) to form d -lactate.
MG that is not catabolized can cross the plasma membrane, where it
accesses pre- or post-synaptic GABAA receptors where it causes GABAA
receptor activation, inward Cl− current, and membrane hyperpolarization,
which is hypothesized to alter behavior.
2002), whereas higher concentrations of MG would be expected
to decrease anxiety. Nevertheless, it remains possible that diabetic
patients experience increased anxiety in spite of increased MG
concentration, since diabetes is clearly associated with numerous
physiological changes in addition to changes in MG concentra-
tion and is correlated with numerous environmental and epi-
demiological factors. Thus, the presence of increased anxiety in
diabetes patients is difficult to interpret.
FUTURE DIRECTIONS
GLO1’S EFFECTS IN FEMALES
Glo1’s effect on anxiety-like behavior has not been assessed in
females. Virtually all of the studies that identified associations
between Glo1 expression and anxiety-like behavior utilized only
male mice (Hovatta et al., 2005; Loos et al., 2009; Benton et al.,
2011), although there are isolated exceptions (Williams et al.,
2009). Studies that directly manipulated Glo1 overexpression by
viral vectors (Hovatta et al., 2005) and BAC transgenes (Distler
et al., 2012) studied behavioral effects in male mice only. It
would not be unprecedented if the behavioral effects of Glo1
are sex-specific; sex differences in anxiety have been described in
both humans and animal models (Palanza, 2001; Hamann, 2005;
McLean and Anderson, 2009). The etiology underlying differen-
tial anxiety between males and females is not well understood, but
it likely includes environmental and hormonal factors (McLean
and Anderson, 2009; Solomon and Herman, 2009; Nillni et al.,
2011).
GLO1 COPY NUMBER AND ANXIETY-LIKE BEHAVIOR IN MICE
Another unresolved issue is that only the BAC transgenic lines
with high Glo1 copy numbers, and correspondingly high Glo1
expression, exhibited increased anxiety-like behavior (Distler
et al., 2012). The initial association between Glo1 copy num-
ber and anxiety-like behavior involved a duplication. In contrast,
B6 and FVB BAC transgenic mice with two additional copies of
Glo1 (equivalent to a homozygous duplication) did not signifi-
cantly differ from wild-type mice in anxiety-like behavior (Distler
et al., 2012). This negative result could reflect inadequate power
to detect a difference or could reflect a true lack of effect of a
Glo1 duplication on anxiety-like behavior. The latter possibility
could be due to differences in Glo1 expression despite equal copy
numbers at the genomic level. Another possibility is that Glo1
overexpression has more robust anxiogenic effects on specific
genetic backgrounds. Consistent with this explanation, Hovatta
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et al. reported that viral-vector-mediated Glo1 overexpression
robustly increased anxiety-like behavior in 129S6/SvEvTac mice
but not B6 mice (Hovatta et al., 2005).
EVOLUTIONARY SIGNIFICANCE
The evolutionary significance of the Glo1 CNV is unknown. Glo1
CNVs are present in both laboratory and wild -caught mice, indi-
cating that the duplicated allele arose prior to the domestication
of mice by mouse fanciers and later scientists (Williams et al.,
2009). While Redon et al. (2006) reported CNVs that included
GLO1 in humans, the underlying data for those particular CNVs
are unconvincing. We are not aware of any other evidence that
GLO1 CNVs are common among humans or any other species;
although it is possible they have simply escaped detection.
MG is byproduct of glycolysis that is generated in every organ-
ism. Homologs of GLO1 exist in bacteria, fungi, plants, and
animals (Cooper, 1984; Yadav et al., 2008; Inoue et al., 2011),
highlighting its ancient physiological importance. Because MG
accumulation is cytotoxic, GLO1’s conservation is likely tied to
its role in cellular survival. The extent to which MG’s action at
GABAA receptors is conserved is unknown. GABA exists in bac-
teria, fungi, plants, and animals (Guthrie and Nicholson-Guthrie,
1989; Rauh et al., 1990; Kumar and Punekar, 1997; Bouche and
Fromm, 2004), though it is only thought to serve as a neurotrans-
mitter among animals; GABAA receptors are prominent among
animals, including invertebrates (Rauh et al., 1990). Therefore, an
important future direction will be to define the evolution of the
relationship between MG and GABAA receptors in other species.
It is possible that MG acts at GABAA receptors in invertebrates;
application of 10–150μM MG had an excitatory effect on the
sixth abdominal ganglion of the cockroach (Davies et al., 1986).
Although GABA is an inhibitory neurotransmitter in insects, it
is also excitatory in some cell types (Beg and Jorgensen, 2003;
Gisselmann et al., 2004).
MG’S BIOPHYSICAL INTERACTIONWITH GABAA RECEPTORS
The discovery that MG activates GABAA receptors has created
an exciting new direction of research. Specifically, studying MG’s
biophysiocal interactions with GABAA receptors is liable to yield
important results. Although MG and GABA are both small
molecules, they are not structurally similar (Figure 2). Therefore,
it is unknown whether they share a binding site on GABAA recep-
tors or whether binding of one prevents binding of the other.
Structural studies are necessary to resolve this question.
Similarly, GABAA receptors are pentamers comprised of var-
ious combinations of at least 16 possible subunits: α1–6, β1–3,
FIGURE 2 | Molecular structures of GABA and MG.
γ1–3, δ, ε, θ, and π (Bollan et al., 2003). Future studies will be
required to identify MG’s receptor subtype selectivity. This is rel-
evant to MG’s behavioral effects, because different subunits and
subunit compositions mediate different GABAergic effects. For
instance, α2 subunits have been reported to mediate the anxi-
olytic effects of benzodiazepines, and α5 subunits are thought
to mediate their sedative effects (Rudolph and Knoflach, 2011).
MG’s activity at different receptor subtypes may contribute to
its endogenous role in the CNS. Future studies will be critical
in identifying the pharmacological and biophysical responses of
specific GABAA receptor compositions to MG.
Future studies will also be important for assessing MG’s activ-
ity at synaptic and extra-synaptic GABAA receptors. Synaptic
GABAA receptors regulate phasic inhibitory signaling, while
extra-synaptic GABAA receptors contribute to tonic inhibitory
signaling (Hablitz et al., 2009) and anxiety (Maguire et al., 2005).
Future studies must directly measure MG’s activity at synaptic
and extra-synaptic receptors in order to determine MG’s role in
phasic and tonic inhibitory signaling.
GLO1’S MECHANISM OF ACTION IN OTHER BEHAVIORAL PHENOTYPES
As reviewed above, two major mechanisms have been ascribed to
GLO1’s behavioral effects: regulating AGE formation and GABAA
receptor activation. These mechanisms are proposed to mediate
GLO1’s role in pain and anxiety, respectively. However, the extent
to which each mechanism underlies the many other behavioral
correlates of GLO1 remains an important area of future investi-
gation. For instance, it is possible that GLO1 regulates depression
through its role in modulating GABAergic tone, given evidence
that deficits in the GABA system have been implicated in depres-
sion (Gerner and Hare, 1981; Petty and Schlesser, 1981; Petty
and Sherman, 1984; Crestani et al., 1999; Earnheart et al., 2007;
Shen et al., 2010; Hasler and Northoff, 2011; Luscher et al., 2011).
Similarly, the mechanism underlying GLO1’s putative involve-
ment in autism remains unknown. Autism has been associated
with high levels of MG and AGEs (Junaid et al., 2004); however,
few studies have examined whether AGEs contribute to autism
(Boso et al., 2006). Alternatively, it is possible that GLO1’s role in
GABAergic signaling could contribute to autism since disruptions
in GABAergic signaling have been identified in autism (Di Cristo,
2007; Rubenstein, 2011). Therefore, additional studies in humans
and mice are required to elucidate the mechanisms underlying
GLO1’s associations with additional behavioral phenotypes.
GLO1 AS A TARGET FOR THERAPEUTIC AGENTS
GLO1 may be a useful target for pharmacological interven-
tion. For instance, GLO1 inhibition was shown to increase MG
concentration and reduce anxiety-like behavior in vivo (Distler
et al., 2012). GLO1 inhibition would represent a novel mecha-
nism of action among psychiatric drugs. Most current anxiolytic
therapies target neurotransmitter systems, including the sero-
tonin and GABA systems (Pollack, 2009). In contrast, GLO1
inhibitors would increase the production of MG, an endogenous
GABAA receptor agonist. This could have a different and pos-
sibly more favorable side-effect profile compared to agents that
allosterically activate GABAA receptors. For instance, endogenous
MG might have receptor subtype specificity, thus preventing
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off-target effects. Similarly, GLO1 inhibition may not increase
MG levels sufficiently to cause sedation or have abuse potential,
which are common concerns of current GABAA receptor agonists.
Development of better GLO1 inhibitors and characterization of
the side-effects of GLO1 inhibition are thus important goals for
future studies.
Studies of the adverse effects of GLO1 inhibition in vivo must
also pay particular attention to cytotoxicity. In vitro studies have
demonstrated that GLO1 inhibition can cause cell death (Kuhla
et al., 2006). Over a short period of time, this is unlikely to
occur in vivo, since GLO1 inhibition was shown to only mod-
estly increase MG levels. Nevertheless, chronic GLO1 inhibition
may increase MG to more toxic levels, causing AGE formation
or cell death. Since AGEs play a prominent role in diabetic com-
plications, GLO1 inhibitors may be a poor choice for patients
with diabetes (Brownlee, 2001). In particular, GLO1 inhibition
was recently shown to exacerbate diabetic hyperalgesia (Bierhaus
et al., 2012), which could limit the use of GLO1 inhibitors,
especially in diabetic patients.
CONCLUSION
Despite a controversial history, recent studies have demonstrated
roles for GLO1 in behavioral phenotypes, including anxiety-
like behavior and pain. Although animal studies support a role
for GLO1 in behavioral phenotypes, human genetic studies are
less convincing. As such, the extent to which polymorphisms in
GLO1 regulate human diseases remains an important direction
for future studies. MG can induce protein modification and acts
as an endogenous GABAA receptor agonist. These cellular func-
tions likely contribute toMG’s behavioral effects. GLO1 inhibitors
may provide novel therapeutic tools for the treatment of CNS
disorders.
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